Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05635357 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
A clinical trial of Breast Cancer, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 16,989
- Enrollment target
- 1
- Study location
NCT05635357: Completed study of Breast Cancer, sponsored by Brigham and Women's Hospital.
NCT05635357 is a study of Breast Cancer that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 16,989 participants, above the 2,789-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (509% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05635357, a study of Breast Cancer, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 16,989 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG Exemestane/Letrozole
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,989 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT05635357 record still lists
NCT05635357 is an observational study that tracks outcomes without assigning an intervention. Its 16,989 participants enrollment target places it among the larger protocols in the corpus, above the 2,789-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (509% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Anastrozole is the first listed.
NCT05635357 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05635357 about?
NCT05635357 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT05635357?
This trial is currently completed. The enrollment target is 16,989 participants. The study started on 2022-11-01. Estimated completion is 2023-12-31.
What conditions does trial NCT05635357 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05635357?
The interventions under investigation include: Anastrozole (DRUG), Exemestane/Letrozole (DRUG).
Who is sponsoring clinical trial NCT05635357?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05635357 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05635357's enrollment target sits among peer trials
16,989 12th of 1224 higher than 1,213 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06479447 · 17,000 participants · NA
Patient Outcome Reporting for Timely Assessments of Life With Post-Traumatic Stress Disorder
- NCT06948838 · 16,895 participants · NA
Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment
- NCT06245187 · 17,198 participants
Get With the Guidelines Atrial Fibrillation Registry
- NCT06951867 · 16,640 participants
Tezspire Cardiac Events PASS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI